"The voice for cancer physicians and their patients in Massachusetts."

  • Home
  • Resources
  • FDA Approvals
  • FDA Approved encorafenib and binimetinib in combination for unresectable or metastatic melanoma with BRAF mutations

FDA Approved encorafenib and binimetinib in combination for unresectable or metastatic melanoma with BRAF mutations

29 Jun 2018 10:46 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration approved encorafenib and binimetinib (Braftovi and Mektovi; Array BioPharma) in combination for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutation, as detected by an FDA-approved test. Read full press release.

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software